



## BryoLogyx Announces Expanded Exclusive Bryostatin Patent License

AUGUST 1, 2019

DANVILLE, Calif (August 1, 2019) --BryoLogyx, Inc., announced today that the Company has acquired additional rights, beyond use in cancer and HIV, for synthetic bryostatin-1 and a wide range of bryostatin analogs under its patent license from Stanford University. The expanded license includes use in a wide range of inflammatory, autoimmune and infectious diseases (excluding brain and central nervous system disorders and liposomal storage diseases); as well as animal health applications.

Financial and other terms were not disclosed.

“This expanded field of use under our license from Stanford significantly strengthens our intellectual property position around synthetic bryostatin towards clinical trials in cancer, to enhance the activity of immune-oncology therapies ...”

“This expanded field of use under our license from Stanford significantly strengthens our intellectual property position around synthetic bryostatin as we advance our initial programs with bryostatin towards clinical trials in cancer, to enhance the activity of immune-oncology therapies,” said Thomas M. Loarie, co-founder, President and CEO of BryoLogyx. “The license also reflects the success of our ongoing collaboration with Paul Wender, Ph.D., a co-founder of BryoLogyx and a noted pioneer in the development of a fully synthetic process for the production of bryostatin and its analogs.”

Clinical and preclinical research conducted to date indicates that these marine-sourced molecules have a very broad range of potential therapeutic applications, notably the enhancement of cancer immunotherapy. The original patent license agreement-- covering uses in cancer and HIV-- between Stanford and the Company had been announced in December, 2018.

Bryostatin-1 is a complex natural product that has generated intense scientific interest at the National Institutes of Health and elsewhere, but whose development as a therapeutic has been limited until now by supply. The patented synthetic production process developed by Dr. Wender enables the cost-effective development of bryostatin-1, as well as the development of next generation, patentable analogs.

## **About BryoLogyx**

BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents. The company's initial focus is on cancer, where it capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development. BryoLogyx has exclusive rights from Stanford University to the method's use in the areas of cancer and HIV. Bryostatin, currently in development for use with immuno-oncology agents, has an established safety profile based on clinical studies involving more than 1100 patients. Learn more at [www.bryologyx.com](http://www.bryologyx.com)

## **Contacts**

Peter Steinerman

Steinerman Biomedical

Tel: 516-641-8959

Email: [prsteinerman@gmail.com](mailto:prsteinerman@gmail.com)